What is Bicara Therapeutics's EPS (diluted)?

Bicara Therapeutics (BCAX) reported EPS (diluted) of -$0.93 in Q1 2026.

How has Bicara Therapeutics's EPS (diluted) changed year-over-year?

Bicara Therapeutics's EPS (diluted) decreased by 36.8% year-over-year, from -$0.68 to -$0.93.

What does EPS (diluted) mean?

Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Bicara Therapeutics BCAX EPS (Diluted)

EPS (Diluted) at other companies

Eli LillyLLY

$8.26+170%

AmgenAMGN

$3.34+4.4%

ArriVent BioPharma, Inc.AVBP

-$0.96+49.5%

ImmunomeIMNM

-$0.48+7.7%

Arcus BiosciencesRCUS

-$1.02+10.5%

Syndax PharmaceuticalsSNDX

-$0.48+51.0%

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.64B+81.4%

Enterprise value$1.32B+288%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's EPS (diluted)?: Bicara Therapeutics (BCAX) reported EPS (diluted) of -$0.93 in Q1 2026.
How has Bicara Therapeutics's EPS (diluted) changed year-over-year?: Bicara Therapeutics's EPS (diluted) decreased by 36.8% year-over-year, from -$0.68 to -$0.93.
What does EPS (diluted) mean?: Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.